中国神经精神疾病杂志
中國神經精神疾病雜誌
중국신경정신질병잡지
CHINESE JOURNAL OF NERVOUS AND MENTAL DISEASES
2014年
8期
479-482
,共4页
高尿酸血症%β-淀粉样肽前体蛋白%β分泌酶-1
高尿痠血癥%β-澱粉樣肽前體蛋白%β分泌酶-1
고뇨산혈증%β-정분양태전체단백%β분비매-1
Hyperuricemia%Amyloid recurosr protein%Beta-site amyloid precursor protein cleaving enzyme-1
目的：观察不同血尿酸水平对大鼠阿尔茨海默病生物标记物β-淀粉样肽前体蛋白（amyloid re-curosr protein，APP）及β分泌酶-1（beta-site amyloid precursor protein cleaving enzyme-1，BACE1）表达的影响。方法采用腹腔注射氧嗪酸钾盐（oxonic acid Potassium salt，OAPS）的方法建立不同水平高尿酸血症（hyperuricemia， HUA）大鼠模型，HE染色观察大鼠海马区形态学变化；Western blot检测海马区APP及BACE1的表达，并进行统计学分析。结果与正常对照组比较，OAPS处理组血尿酸水平明显升高（P<0.01），海马区APP及BACE1的表达明显上调（P<0.001），与低剂量组比较，中、高剂量组血尿酸水平升高（P<0.05），海马区APP及BACE1表达减少（P<0.05），与中剂量组比较，高剂量组血尿酸水平增高（P<0.01），高剂量组的大鼠海马组织APP的表达减少（P<0.05），BACE1表达无统计学差异性（P>0.05）。结论高于正常水平的血尿酸可能为AD发生或发展的危险因素，其水平越高对AD危险性越低。
目的：觀察不同血尿痠水平對大鼠阿爾茨海默病生物標記物β-澱粉樣肽前體蛋白（amyloid re-curosr protein，APP）及β分泌酶-1（beta-site amyloid precursor protein cleaving enzyme-1，BACE1）錶達的影響。方法採用腹腔註射氧嗪痠鉀鹽（oxonic acid Potassium salt，OAPS）的方法建立不同水平高尿痠血癥（hyperuricemia， HUA）大鼠模型，HE染色觀察大鼠海馬區形態學變化；Western blot檢測海馬區APP及BACE1的錶達，併進行統計學分析。結果與正常對照組比較，OAPS處理組血尿痠水平明顯升高（P<0.01），海馬區APP及BACE1的錶達明顯上調（P<0.001），與低劑量組比較，中、高劑量組血尿痠水平升高（P<0.05），海馬區APP及BACE1錶達減少（P<0.05），與中劑量組比較，高劑量組血尿痠水平增高（P<0.01），高劑量組的大鼠海馬組織APP的錶達減少（P<0.05），BACE1錶達無統計學差異性（P>0.05）。結論高于正常水平的血尿痠可能為AD髮生或髮展的危險因素，其水平越高對AD危險性越低。
목적：관찰불동혈뇨산수평대대서아이자해묵병생물표기물β-정분양태전체단백（amyloid re-curosr protein，APP）급β분비매-1（beta-site amyloid precursor protein cleaving enzyme-1，BACE1）표체적영향。방법채용복강주사양진산갑염（oxonic acid Potassium salt，OAPS）적방법건립불동수평고뇨산혈증（hyperuricemia， HUA）대서모형，HE염색관찰대서해마구형태학변화；Western blot검측해마구APP급BACE1적표체，병진행통계학분석。결과여정상대조조비교，OAPS처리조혈뇨산수평명현승고（P<0.01），해마구APP급BACE1적표체명현상조（P<0.001），여저제량조비교，중、고제량조혈뇨산수평승고（P<0.05），해마구APP급BACE1표체감소（P<0.05），여중제량조비교，고제량조혈뇨산수평증고（P<0.01），고제량조적대서해마조직APP적표체감소（P<0.05），BACE1표체무통계학차이성（P>0.05）。결론고우정상수평적혈뇨산가능위AD발생혹발전적위험인소，기수평월고대AD위험성월저。
Objective To observe the effects of the different serum uric acid levels on expression of Alzheimer’s disease biomarkers (APP and BACE1) in rats. Methods Intraperitoneal injection of oxygen of oxazine acid potassium was used to produce HUA models in rats. H&E staining was used to detect the morphological changes of the hippocampus. Western blot was used to detect the protein levels of APP and BACE1 of the hippocampus. Results Compared with nor-mal control group, the serum uric acid and the protein levels of APP and BACE1 in the hippocampus was obviously in-creased at OAPS treatment group (P<0.01). Compared with low dose OAPS treatment group, the serum uric acid level was significantly increased whereas the protein levels of APP and BACE1 in the hippocampus were significantly decreased at the middle and high dose group (P<0.01). Compared with middle dose group, the serum uric acid level was increased at high dose group (P<0.05) and the expression of APP were decreased in the hippocampus rats but the expression of BACE1 remained unchanged (P>0.05). Conclusion The higher level of serum uric acid may be a protective factor of AD. The higher serum uric acid levels, the lower the risk of AD.
